Tardive dyskinesia

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
1 Unique sponsors
1 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase II: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

3 trials
  • Adeptio Pharmaceuticals Limited Commercial
    (2R,3R,11BR)-1,3,4,6,7,11B-HEXAHYDRO-9,10-DIMETHOXY-3-(2-METHYLPROPYL)-2H-BENZO[A]QUINOLIZIN-2-OL
    2023-509518-12-01 2 countries 2024 n=70
    Recruiting
  • Adeptio Pharmaceuticals Limited Commercial
    (2R,3R,11BR)-1,3,4,6,7,11B-HEXAHYDRO-9,10-DIMETHOXY-3-(2-METHYLPROPYL)-2H-BENZO[A]QUINOLIZIN-2-OL
    2024-516852-17-00 4 countries 2023 n=102
    Recruiting
  • Adeptio Pharmaceuticals Limited Commercial
    (2R,3R,11BR)-1,3,4,6,7,11B-HEXAHYDRO-9,10-DIMETHOXY-3-(2-METHYLPROPYL)-2H-BENZO[A]QUINOLIZIN-2-OL
    2024-519105-35-00 1 country 2023 n=6
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Adeptio Pharmaceuticals Limited Commercial 3 Phase II 2
New trials by year
2023
2
2024
1
← All indication landscapes